Investors

New Enterprise Associates (NEA) is a venture capital firm specializing in investments in venture growth equity at all points of developments with a 60 percent focus on seed and start-up stage companies. The firm prefers to invest in the information technology sector with a focus on communications, software and services, and electronics industries and the healthcare sector with a focus on energy technology, biopharmaceuticals, medical devices, healthcare services, and healthcare information technology industries.

Mohr Davidow Ventures is a venture capital firm specializing in seed and early stage investments. The firm typically invests in information technology, energy and materials, and life sciences companies. Within information technology it invests in Internet services including developing and marketing web-enabled applications and services; semiconductors including semiconductor design, process technology, tools and related hardware, and software infrastructure; and software and systems including systems and applications development and systems engineering.

Frazier Healthcare Ventures is principal investment firm. The firm specializes in growth equity financing; expansion stage equity; recapitalizations; buyouts; spinouts; shareholder liquidity; early stage investments including seed and Series A and B financing rounds; late stage investments including Series C, D and PIPEs investments; and de novo investments across all stages of a company’s development. It seeks to invest in the biopharmaceutical, medical device, and healthcare service sectors.

Bio Fund Management Ltd. is an investment arm of Capinordic AS specializing in investments in early stage, growth capital, expansion capital, turnaround, restructuring, management buyouts, and management buyins. The firm seeks to invest in life sciences, pharmaceuticals, medical technologies, nutrition, and environmental technologies.

Aberdeen Asset Managers Private Equity Ltd. is a private equity firm specializing in management buyouts, buy-ins, turnarounds, acquisition finance, replacement capital, and developmental capital investments. The firm also invests growth capital in new and secondary AIM issues. It prefers to invest in support services, specialist manufacturing, consumer and leisure, and financial services sectors. The firm typically invests in companies based in the United Kingdom. It seeks to invest between £1 million ($1.86 million) and £20 million ($37.3 million).

Takeda Research Investment, Inc. is a venture capital investment arm of Takeda Pharmaceutical Company Limited specializing in start up, seed, and Series ‘A’ investments. It may also consider later rounds of investment (second, third, or mezzanine). The firm prefers to invest in drugs and biotherapeutics with a focus on cardiovascular, central nervous system, metabolic, and oncology therapeutic domains. It does not invest in gene therapy or anti-infective products, medical devices, or diagnostics devices. The firm prefers to co-invest as a minority stake holder.

Sofinnova Partners is a venture capital firm seeking to invest in startup early stage, and corporate spin-offs. It invests in companies in the information technology and life sciences sectors. Within the technology sector, the firm seeks to invest in companies in sectors such as telecommunication, consumer electronics, and wireless devices; Internet, ecommerce, and wireless internet; other technologies and markets such as energy and photonics; clean technology.

S.R. One Ltd. is an investment arm of Glaxosmithkline plc specializing in investment in emerging companies with products that are in preclinical development stage through clinical proof-of-concept. The firm prefers to invest in pharmaceuticals, biotech, healthcare, and related information technologies companies that are focused on drug discovery, development, and delivery. It seeks to invest in companies based globally with a focus on North America and Europe.

Edmond de Rothschild Investment Partners is the investment arm of La Compagnie Financière Edmond de Rothschild specializing in private equity and venture capital transactions. The firm typically invests in companies needing to expand (organically or via build up) or facing transmission issues, pre-IPO, private investment in public equities (PIPEs), and public to private transactions. It primarily makes investments in life sciences, information technology, industrial, and services sector.

Abingworth Management Limited is a venture capital firm specializing in investments in early stage, seed/start-ups, and development capital opportunities. The firm focuses on healthcare, life sciences, biomedical, biotechnology, and medical devices companies. It invests in companies based in the U.S. and Europe. The firm’s investments generally range between $1 million and $25 million averaging around $15 million per investment after all rounds of financing in its portfolio companies. It can also invest in a syndicate of investors to raise up to $50 million.